XML 38 R22.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 1 - Significant Accounting Policies and Concentrations of Risk (Tables)
 12 Months Ended
Dec. 31, 2017
Notes Tables  
Available-for-sale Securities [Table Text Block]
    December 31, 2017
    Amortized
Cost		   Accrued
Interest		   Gross
Unrealized
Gains		   Gross
Unrealized
Losses		   Estimated
Fair Value
Obligations of U.S. Government and its agencies   $
60,121
     $
177
     $
—
     $
(122
 )   $
60,176
  
Corporate debt securities    
34,021
      
203
      
—
      
(108
 )    
34,116
  
Certificates of deposit    
11,099
      
32
      
1
      
(14
 )    
11,118
  
Total investments   $
105,241
     $
412
     $
1
     $
(244
 )   $
105,410
  
    December 31, 2016
    Amortized
Cost		   Accrued
Interest		   Gross
Unrealized
Gains		   Gross
Unrealized
Losses		   Estimated
Fair Value
Obligations of U.S. Government and its agencies   $
20,266
     $
34
     $
2
     $
(4
 )   $
20,298
  
Corporate debt securities    
6,179
      
26
      
2
      
(8
 )    
6,199
  
Certificates of deposit    
14,962
      
17
      
7
      
(11
 )    
14,975
  
Total investments   $
41,407
     $
77
     $
11
     $
(23
 )   $
41,472
  
Available For Sale Securities Debt Maturities Fair Value [Table Text Block]
    2017   2016
Maturing in one year or less   $
64,115
     $
32,546
  
Maturing after one year through two years    
34,257
      
8,926
  
Maturing after two years    
7,038
      
—
  
Total investments   $
105,410
     $
41,472
  
Schedule of Receivables from Collaborations [Table Text Block]
    December 31, 2017
    Billed   Unbilled   Total
U.S. Department of Health and Human Services   $
42
     $
2,020
     $
2,062
  
Shionogi & Co. Ltd.    
1,600
      
—
      
1,600
  
Green Cross Corporation    
1,388
      
28
      
1,416
  
Mundipharma International Holdings Limited    
47
      
—
      
47
  
Seqirus UK Limited    
825
      
167
      
992
  
Total receivables   $
3,902
     $
2,215
     $
6,117
  
    December 31, 2016
    Billed   Unbilled   Total
U.S. Department of Health and Human Services   $
—
     $
3,495
     $
3,495
  
Shionogi & Co. Ltd.    
3,451
      
—
      
3,451
  
Green Cross Corporation    
686
      
—
      
686
  
Seqirus UK Limited    
957
      
179
      
1,136
  
Total receivables   $
5,094
     $
3,674
     $
8,768
  
Schedule of Accrued Liabilities [Table Text Block]
    December 31,
    2017   2016
Compensation and benefits   $
2,905
     $
425
  
Development costs    
6,683
      
7,427
  
Inventory    
—
      
705
  
Professional fees    
729
      
242
  
Duties and taxes    
148
      
56
  
Other    
2,234
      
1,981
  
Total accrued expenses   $
12,699
     $
10,836
  
Schedule of Revenues from Collaborations [Table Text Block]
    2017   2016   2015
Product sales, net   $
1,501
     $
2,269
     $
6,291
  
Royalty revenue    
10,543
      
9,682
      
2,386
  
Collaborative and other research and development revenues:                        
U.S. Department of Health and Human Services    
4,608
      
12,449
      
16,337
  
Green Cross Corporation    
—
      
—
      
132
  
Shionogi & Co. Ltd.    
1,184
      
1,184
      
1,184
  
Seqirus UK Limited    
7,350
      
769
      
21,927
  
Total collaborative and other research and development revenues    
13,142
      
14,402
      
39,580
  
Total revenues   $
25,186
     $
26,353
     $
48,257